Undescended Testicle Market to reach US$ 8.65 Bn by 2032

The undescended testicle market, projected to reach a valuation of US$ 5.21 billion in 2025, is set for steady growth. Estimates indicate the market will grow to US$ 8.65 billion by 2032, registering a CAGR of 7.5% during the forecast period. Key market drivers include the increasing awareness and early diagnosis of congenital abnormalities, advancements in pediatric surgical procedures, and improved access to healthcare in emerging regions. Moreover, ongoing research into hormonal and non-invasive treatment options, along with supportive government initiatives and healthcare policies, is expected to propel the market expansion.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/global-undescended-testicle-market

The global undescended testicle market is witnessing steady expansion, driven by the rising incidence of congenital anomalies in newborns—particularly among preterm male infants—and growing awareness of early intervention benefits. Increasing utilization of neonatal screening programs, improved diagnostic capabilities, and greater awareness among pediatricians and caregivers have led to the earlier identification and treatment of cryptorchidism, fueling demand for both hormonal and surgical therapies such as hCG, GnRH analogs, and minimally invasive orchidopexy procedures.

For instance, a nationwide population-based surveillance study titled “Prevalence of Congenital Cryptorchidism in China: 2007–2021”, published in July 2024, analyzed data from over 2.5 million full-term male births. The study reported a significant rise in cryptorchidism prevalence, increasing from 3.86 to 11.20 per 10,000 live births, with an average annual percent change (AAPC) of 7.9%. This finding underscores the growing burden of congenital testicular disorders and highlights the need for proactive neonatal health strategies.

Additionally, pediatric urology and endocrinology communities worldwide are emphasizing early referral protocols, while healthcare systems in developed and emerging economies alike are investing in advanced imaging and surgical techniques. These dynamics are reinforcing clinical best practices and improving long-term reproductive outcomes.

However, the market still faces challenges, including limited access to specialized pediatric care in low-resource settings, variations in diagnostic standards, and cultural barriers to early surgical interventions. Despite these hurdles, ongoing research, policy support, and global awareness campaigns are expected to sustain momentum in the undescended testicle market through the forecast period.

Increased public and healthcare provider awareness about the long-term complications of untreated cryptorchidism—such as infertility and testicular cancer—is leading to earlier diagnosis and intervention. Governments and healthcare organizations are promoting neonatal screening programs, which is driving the demand for early treatment options like hormonal therapies and pediatric surgeries.

In 2024, the Luxembourg Cancer Foundation launched an awareness campaign highlighting the risks associated with undescended testicles, such as increased chances of testicular cancer. The campaign encouraged men to perform regular self-examinations and consult healthcare providers if abnormalities are detected.

The growing adoption of minimally invasive procedures, such as laparoscopic orchiopexy, is a significant trend. These techniques offer quicker recovery times, lower complication rates, and improved cosmetic outcomes, making them increasingly preferred by healthcare providers and patients alike. This is boosting the demand for advanced surgical instruments and training in pediatric urology.

A prospective study published in Pediatric Surgery International in January 2024 evaluated single-site laparoscopic orchiopexy for palpable undescended testes in children. The study found that this technique offered superior cosmetic results with no visible abdominal scarring and comparable success rates to conventional laparoscopic methods. Initially, the operating time was longer for the single-site group, but it became similar to the conventional group over time. The success rates were nearly identical, and no significant differences were observed in complications or testicular ascent between the groups.

Artificial intelligence (AI) and advanced imaging technologies such as high-resolution ultrasound and MRI are increasingly being integrated into pediatric urology to improve the accuracy and speed of cryptorchidism diagnosis. These technologies enable non-invasive, precise localization of non-palpable testes and better pre-surgical planning, reducing unnecessary exploratory surgeries and improving outcomes.

For instance, studies have demonstrated that AI systems can achieve approximately 90% accuracy in identifying undescended testicles by recognizing specific image patterns, significantly reducing diagnostic time and enhancing follow-up processes.

Furthermore, combining diffusion-weighted imaging (DWI) with conventional MRI has shown to improve the detection of viable abdominal and inguinal testes. A study involving 60 pediatric patients reported that the combined approach increased sensitivity to 92.86% and specificity to 100%, compared to 85.71% and 100%, respectively, with conventional MRI alone.

There is an emerging trend toward personalized treatment regimens combining hormonal therapies and surgery tailored to individual patient characteristics such as age, testicular position, and fertility potential. Multimodal approaches are proving to optimize outcomes by reducing surgery rates and preserving testicular function. This trend is driving demand for integrated treatment protocols and specialist pediatric urology centers offering comprehensive care.

In December 2024, meta-analysis reviewed the effectiveness of recombinant follicle-stimulating hormone (rFSH) and human chorionic gonadotropin (hCG) combination therapy in inducing spermatogenesis and increasing testicular volume. The analysis found that this combination therapy was significantly more effective than hCG alone, particularly in patients with small testes (<4 mL), suggesting its potential role in personalized treatment regimens.

“The global undescended testicle market is progressing steadily, driven by heightened awareness, evolving treatment modalities, and expanding neonatal screening protocols,” explains Mr. Ghanshyam Shrivastava, a Principal Consultant. “As pediatric care becomes more proactive, earlier diagnosis and intervention are becoming standard practice, especially in developed regions where neonatal health infrastructure is robust. This is accelerating the adoption of hormone therapies as first-line treatments and expanding access to minimally invasive surgical procedures.”

“Advancements in diagnostic and surgical technologies are reshaping the clinical landscape. High-resolution imaging, combined with AI-powered diagnostic support, is enhancing the precision and speed of cryptorchidism detection, reducing unnecessary exploratory surgeries. Meanwhile, innovations in laparoscopic and robotic-assisted orchiopexy are improving outcomes with shorter recovery times and reduced complication risks, which appeals to both patients and providers.”

“Looking ahead, the shift toward personalized, multimodal treatment strategies marks a critical evolution in the market. Combination therapies—such as rFSH and hCG—are showing improved outcomes in testicular development and fertility preservation, suggesting a future where individualized care pathways become the norm. With emerging economies investing in pediatric urology infrastructure and policy frameworks aligning with global best practices, the market is well-positioned for sustained growth driven by quality, access, and innovation.”

Key players in the undescended testicle market include: